The Group's principal activities are development and production of vaccines and immune therapy products. The Group applies gene therapy and new methodologies in vaccine delivery. The Group utilises three proprietary delivery technologies for its product development programmes: a pox virus vector, a retroviral vector and a cell encapsulation technology. The main product of the Group is the manufacture of smallpox vaccine. The ongoing clinical programmes involve HIV, malignant melanoma, smallpox and cancer research. The Group operates in Denmark, Germany, the US and Singapore.
Alacra Alerts:
Receive alerts on the latest reports on Bavarian Nordic A/S
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
